INVESTORS

Investor Relations

Recent News
Dec 2, 2019

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with...

Nov 26, 2019

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

Nov 20, 2019

- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic...

View all news releases

Events and Webcasts
Saturday, December 7, 2019 - Tuesday, December 10, 2019

Location: Orlando, FL Visit Sierra Oncology’s booth #1066 to speak with our team of experts! To schedule a meeting, email info@sierraoncology.com

View all events and webcasts

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts